The aim of the study is to create the evidence base to underpin clinically and cost effective prescribing
of the biologic drugs IFX and aIFN for BD.
The objectives of the study are to:
1. Undertake a randomised controlled trial to compare IFX versus aIFN in patients with BD who
are unresponsive to standard oral therapy
2. Examine whether IFNL3 and IFNL4 SNPs can predict response to aIFN and/or IFX in BD
3. Examine the potential for urine metabolomics to act as biomarker for drug response to IFX
and/or aIFN in BD